Moreover, BRAF inhibitors (vemurafenib, dabrafenib, and encorafenib) cannot be used as single drugs to treat mutant NRAS melanoma, because they paradoxically increase the MAPK/ERK signaling and, consequently, tumor proliferation [42,43]. This evidence concerns the gene MAPK1 and neoplasm.